Atossa Therapeutics Inc. (ATOS) Financial Statements (2024 and earlier)
Company Profile
| Business Address |
10202 5TH AVENUE NE SEATTLE, WA 98125 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) (USD)
| 6/30/2024 MRQ | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 88,460,000 | 110,890,000 | 136,377,000 | 39,553,671 | 12,581,136 | 10,380,493 | |||
| Cash and cash equivalents | 88,460,000 | 110,890,000 | 136,377,000 | 39,553,671 | 12,581,136 | 10,380,493 | |||
| Restricted cash and investments | 110,000 | 110,000 | 110,000 | 110,000 | 110,000 | 110,000 | |||
| Prepaid expense | 2,162,000 | 4,031,000 | 2,488,000 | 1,813,902 | 862,344 | 509,833 | |||
| Other current assets | 2,423,000 | 1,193,000 | 657,662 | 26,130 | 30,942 | ||||
| Other undisclosed current assets | 1,487,000 | 743,000 | 1,072,000 | 634,940 | 739,656 | 518,098 | |||
| Total current assets: | 92,219,000 | 118,197,000 | 141,240,000 | 42,770,175 | 14,319,266 | 11,549,366 | |||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 18,053 | 50,479 | ✕ | ||||||
| Property, plant and equipment | 20,000 | 20,632 | 34,350 | 54,487 | |||||
| Other noncurrent assets | 2,323,000 | 635,000 | 2,000 | 17,218 | 17,218 | 17,218 | |||
| Other undisclosed noncurrent assets | 1,710,000 | 4,700,000 | 13,375 | 68,542 | 99,375 | ||||
| Total noncurrent assets: | 4,033,000 | 5,335,000 | 22,000 | 69,278 | 170,589 | 171,080 | |||
| TOTAL ASSETS: | 96,252,000 | 123,532,000 | 141,262,000 | 42,839,453 | 14,489,855 | 11,720,446 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 1,779,000 | 4,024,000 | 3,105,000 | 2,645,645 | 1,270,479 | 1,465,472 | |||
| Employee-related liabilities | ✕ | ✕ | ✕ | 1,184,000 | 963,665 | 899,420 | 935,070 | ||
| Accounts payable | 806,000 | 2,965,000 | 1,717,000 | 1,588,613 | 293,171 | 353,328 | |||
| Accrued liabilities | 973,000 | 1,059,000 | 204,000 | 93,367 | 77,888 | 177,074 | |||
| Debt | 39,371 | ||||||||
| Deferred compensation liability | 1,410,025 | ||||||||
| Other liabilities | 1,803,000 | 19,000 | 21,000 | 4,748 | 12,892 | 39,939 | |||
| Other undisclosed current liabilities | 1,654,000 | 1,525,000 | 13,021,128 | ||||||
| Total current liabilities: | 5,236,000 | 5,568,000 | 3,126,000 | 15,671,521 | 1,322,742 | 2,915,436 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation: | 11,108 | ||||||||
| Operating lease, liability | 11,108 | ✕ | |||||||
| Total noncurrent liabilities: | 11,108 | ||||||||
| Total liabilities: | 5,236,000 | 5,568,000 | 3,126,000 | 15,671,521 | 1,333,850 | 2,915,436 | |||
| Equity | |||||||||
| Equity, attributable to parent, including: | 91,016,000 | 117,964,000 | 138,136,000 | 27,167,932 | 13,156,005 | 8,805,010 | |||
| Preferred stock | 1 | 1 | 2 | ||||||
| Common stock | 22,792,000 | 22,792,000 | 22,792,000 | 8,558,778 | 1,643,565 | 1,052,372 | |||
| Treasury stock, value | (1,475,000) | ||||||||
| Additional paid in capital | 255,987,000 | 250,784,000 | 243,996,000 | 129,887,146 | 105,583,479 | 84,583,899 | |||
| Accumulated deficit | (186,288,000) | (156,194,000) | (129,234,000) | (111,898,992) | (94,071,040) | (76,831,263) | |||
| Other undisclosed equity, attributable to parent | 582,000 | 582,000 | 620,999 | ||||||
| Total equity: | 91,016,000 | 117,964,000 | 138,136,000 | 27,167,932 | 13,156,005 | 8,805,010 | |||
| TOTAL LIABILITIES AND EQUITY: | 96,252,000 | 123,532,000 | 141,262,000 | 42,839,453 | 14,489,855 | 11,720,446 | |||
Income Statement (P&L) (USD)
| 6/30/2024 TTM | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | ||
|---|---|---|---|---|---|---|---|---|
| Operating expenses | (31,377,000) | (27,691,000) | (20,521,000) | (14,607,392) | (17,265,425) | (11,434,233) | ||
| Operating loss: | (31,377,000) | (27,691,000) | (20,521,000) | (14,607,392) | (17,265,425) | (11,434,233) | ||
| Nonoperating income (expense) | 4,273,000 | 731,000 | (85,000) | 50,801 | 25,648 | 29,299 | ||
| Investment income, nonoperating | 4,343,000 | 877,000 | ||||||
| Other nonoperating income (expense) | (70,000) | (146,000) | (85,000) | 50,801 | 25,648 | 29,299 | ||
| Loss from continuing operations before equity method investments, income taxes: | (27,104,000) | (26,960,000) | (20,606,000) | (14,556,591) | (17,239,777) | (11,404,934) | ||
| Other undisclosed loss from continuing operations before income taxes | (2,990,000) | (3,271,361) | ||||||
| Loss from continuing operations: | (30,094,000) | (26,960,000) | (20,606,000) | (17,827,952) | (17,239,777) | (11,404,934) | ||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | (20,606,000) | (17,827,952) | (17,239,777) | (11,404,934) | |
| Net loss attributable to parent: | (30,094,000) | (26,960,000) | (20,606,000) | (17,827,952) | (17,239,777) | (11,404,934) | ||
| Other undisclosed net loss available to common stockholders, basic | (4,502,799) | (11,479,308) | ||||||
| Net loss available to common stockholders, diluted: | (30,094,000) | (26,960,000) | (20,606,000) | (22,330,751) | (17,239,777) | (22,884,242) | ||
Comprehensive Income (USD)
| 6/30/2024 TTM | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (30,094,000) | (26,960,000) | (20,606,000) | (17,827,952) | (17,239,777) | (11,404,934) | ||
| Comprehensive loss, net of tax, attributable to parent: | (30,094,000) | (26,960,000) | (20,606,000) | (17,827,952) | (17,239,777) | (11,404,934) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.